Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden 0.5 hours per response..

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)														
1. Name and Address of Reporting Person * Steinhart Richard I				2. Issuer Name and Ticker or Trading Symbol Actinium Pharmaceuticals, Inc. [ATNM]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X. Director 10% Owner				
	ÍNIUM PI	(First) HARMACEUTION VENUE, THIRD	CALS,	3. Date of 12/16/20		liest Tra	nsacti	ion (Month	/Day/Y	ear)		Officer (giv	re title below)	Ot	her (specify below	v)
(Street) NEW YORK, NY 10017				4. If Amendment, Date Original Filed(Month/Day/Year)							_X_1	6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
NEW YC		(State)	(Zip)			Tabl	le I -	Non-Deriv	ative S	ecurities				eficially Ow		
(Instr. 3) Date		2. Transaction Date (Month/Day/Year)			nte, if Ci		(4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		of (D) Owr Tran) .		6. Ownership Form:	7. Nature of Indirect Beneficial Ownership	
				(Month/Day/Year		i cai)	Code	e V	mount	(A) or (D)	Price	su. 3 anu 4)			or Indirect (I) (I) (Instr. 4)	
			Table II - I					contai form d	ned in isplays	this for s a curr , or Beno	m are not ently valid	required OMB c	n of inform d to respo ontrol num	nd unless t		474 (9-02)
1. Title of Derivative Security (Instr. 3)	Conversion	(Month/Day/Year)	3A. Deemed Execution Date, if	4. 5. N Transaction of Code Deri (Instr. 8) Sect Acq (A) Disp (D) (Instr. 8) Instruction of Deri (Instr. 8) Sect (Instr. 8) Se		5. Number of Derivate Securiti Acquire (A) or Dispose (D)	Number 6. Date Expirative urities quired or posed of str. 3, 4,		ration Date Amo nth/Day/Year) Und Secu		7. Title and Amount of Underlying Securities (Instr. 3 and	f B		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownersh Form of Derivativ Security: Direct (D or Indirect	(Instr. 4)
				Code	v	(A)	(D)	Date Exercisab		ration	Title	Amount or Number of Shares				
Options to purchase common	\$ 6.7	12/16/2013		A		49,950		<u>(1)</u>	12/1	6/2023	Common stock	49,950	\$ 6.7	49,950	D	

Reporting Owners

Depositing Owner Name / Adduces	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Steinhart Richard I C/O ACTINIUM PHARMACEUTICALS, INC 501 FIFTH AVENUE, THIRD FLOOR NEW YORK, NY 10017	X						

Signatures

/s/ Richard I Steinhart	12/24/2013
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Options granted on December 16, 2013 to purchase an aggregate of 49,950 shares of common stock. A total of 28% of the options will vest one year from the grant date, and 2% per month thereafter. As of the date of this report, no options have vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.